Three new drugs made in Beijing

After the Spring Festival, "pirfenidone", a new drug for the treatment of idiopathic pulmonary fibrosis, went on the market The production acceptance of the vaccine for the prevention of HFMD was completed The new antitumor drug "loratrak hydrochloride" has been declared for production The reporter recently learned from the Beijing food and drug administration that three national first-class new drugs developed by the city and with independent intellectual property rights will be launched in a centralized manner within the year, which will significantly reduce patients' pain and treatment costs This is also the first time in many years that the concentration of national first-class new drugs has been "settled" in Beijing A new national first-class drug for the treatment of "idiopathic pulmonary fibrosis" is expected to go on the market after the Spring Festival, which will break the current situation that there is no medicine for this disease The pirfenidone capsule developed and produced by Beijing Contini Pharmaceutical Co., Ltd is the second approved class 1.1 innovative drug in the world, which fills the gap in this field in China and keeps pace with foreign technology "Idiopathic pulmonary fibrosis" is also known as "cancer other than cancer" The lung function of the patients continues to decline, and the average survival period is only 2 to 5 years Once the patient's lung becomes a fibrotic "honeycomb lung", sneezing, coughing and catching a cold can kill the patient The incidence rate of incidence of disease in the past few years is very low In recent years, the incidence rate of the city is increasing, and the incidence of the disease is expanding However, there is no effective treatment "There are 14.7 cases per 100000 people, increasing at an annual rate of 11%." According to Dr Luo Ying, chairman and chief scientist of Contini company, there are 3000 to 5000 people suffering from the disease every year in the country who have no medicine to treat The union hospital alone receives 2300 patients every year In 2006, the clinical study of pirfenidone was organized by union hospital In 2010, pirfenidone passed the new drug review In 2012, "the process upgrading and production line construction project of pirfenidone, a new drug for the treatment of pulmonary fibrosis, was included in the major equity investment project of the national government The equity financing of Beijing Municipal Science and Technology Commission was 10 million yuan, which was held by Zhongguancun Development Group "The marketing of pirfenidone will bring new hope to patients with pulmonary fibrosis." Luo Ying introduced that after 10 years of independent research and development and three-phase experiments, it has been proved that the drug can reduce disease progress and mortality by 29%, significantly improve vital capacity, blood oxygen concentration indicators, reduce symptoms such as poor breathing and suffocation The domestic price of pirfenidone will be half of the price listed in the EU, and the sales volume is expected to reach 200-300 million yuan in the first year after listing In order to deliver the "life-saving medicine" to the people in the first time, the Municipal Food and drug administration, under the premise of strict quality control, opened a "green channel" for innovative drugs, cutting off the "queuing" time that often takes one or two years "To improve the speed of examination and approval of innovative drugs is determined by their breakthrough of traditional significance." According to the relevant person in charge of the drug production supervision office of SFDA, the national class 1.1 new drug refers to the drug that is not marketed at home and abroad, and the raw material drug and its preparation are prepared by synthetic or semi synthetic methods The success rate of this kind of extraction and screening compound is only one in ten million At present, most of the research and development of generic drugs in China are in three, four and five categories, and few of them are really national first-class new drugs The reporter learned that in addition to the soon to be listed pirfenidone, Beijing Kexing Biological Products Co., Ltd.'s HFMD vaccine has completed the production site acceptance, and Beijing Kangchen pharmaceutical's new anti-tumor drug "loratrak hydrochloride" has been declared for production After the three varieties of new drugs are listed, the market capacity is expected to exceed 1 billion yuan According to the analysis of the person in charge of SFDA, the national first-class new drugs are concentrated in Beijing, benefiting from the good regulatory and development environment of the capital's pharmaceutical industry, which is the result of the long-term policy, technology and financial support of the government, achieving the strategic development goal of "two to three first-class new drugs" settled in Beijing during the 12th Five Year Plan period driven by innovation in the biomedical industry The person in charge pointed out that the centralized implementation of these three new drugs will not only vigorously promote the development of the pharmaceutical economy in the capital, but also inevitably bring more social benefits In the future, the majority of patients will not only get safer and more effective "made in Beijing" new drugs, but also need to pay far less than the cost of imported drugs, which will significantly reduce the economic burden of patients and the country, and truly let the achievements of innovation and development of the pharmaceutical industry benefit the people, so that the health benefits are implemented Original title: boost the innovation and development of pharmaceutical enterprises, three "made in Beijing" new drugs are launched in a centralized way